New Trial Granted Because Nealy All of the Defendant S Noninfringement Evidence Was Untimely
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Matthew J. Petersen and Jeremy Anapol
TRUDELL MED. INT’L INC. V. D R BURTON HEALTHCARE, LLC
Before Moore, Chen, and Stoll. Appeal from the U.S. District Court for the Eastern District of North Carolina.
Summary: The district court erred by admitting untimely expert testimony on noninfringement and by refusing to grant a new trial after the jury found noninfringement.
Trudell Medical International (“Trudell”) sued D R Burton Healthcare (“Burton”) for patent infringement. Burton disclosed expert testimony on noninfringement after the discovery cut-off and less than three weeks before trial. The district court denied Trudell’s motion to exclude Burton’s late expert testimony and the jury found no infringement. Trudell moved for a new trial. The court denied the motion and Trudell appealed.
The Federal Circuit reversed the district court’s decision admitting the untimely expert testimony. The delay was not harmless because Burton’s expert testimony “constituted nearly all” of its noninfringement evidence and because Trudell was unable to depose the expert before trial. Separately, the Federal Circuit found the expert testimony deficient under FRE 702 and Daubert because it disregarded the district court’s claim constructions.
Because the district court’s admission of the expert testimony was not harmless, the Federal Circuit reversed the district court’s decision declining to grant a new trial. The Federal Circuit also granted Trudell’s request to reassign the case on remand because the judge made objectionable statements throughout the trial, including complaints about Trudell’s counsel that the judge made in front of the jury.
Editor: Sean Murray
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…